Dual-target, High-dose TMS for PD Patients With FOG (NCT05625386) | Clinical Trial Compass
TerminatedNot Applicable
Dual-target, High-dose TMS for PD Patients With FOG
Stopped: The study was halted at the midpoint because the interim analysis demonstrated a large effect size of the DHT group compared with the SCT group (Cohen's d = 1.58).
China64 participantsStarted 2022-12-22
Plain-language summary
The aim of the current study was to verify whether high-dose TMS treatment of the motor and cognitive cortices is more effective in alleviating FOG than conventional-dose TMS of the motor cortex only. Specifically, investigator hypothesized that the effect of dual-target TMS on FOG is better than traditional stimulation of the motor cortex only, and the effect of high-dose TMS is better than conventional doses.
Who can participate
Age range40 Years – 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. diagnosis of FOG with expertise in movement disorders.
✓. the score of item 3 of the FOG questionnaire ≥1.
✓. ongoing treatment with a stable dose of any medication for 2 months.
✓. 40 years of age or older.
Exclusion criteria
✕. a history of addiction, psychiatric disorders, or neurological diseases other than PD.
✕. focal brain lesions on T1-/T2-weighted fluid-attenuated inversion recovery images.
✕. anti-PD medication adjustments during rTMS treatment.
✕. history of substance abuse within the past 6 months.
✕. nonremovable metal objects in or around the head.
✕. previously received rTMS treatment.
✕
What they're measuring
1
The Freezing of Gait Questionnaire (FOGQ) scores
Timeframe: the changes in FOGQ scores from baseline to 1 month after completion of TMS (follow-up).